HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody.

Abstract
We have reported a 27% overall anti-tumor response using i.p. immunotherapy of advanced ovarian carcinoma with autologous, ex vivo expanded, T lymphocytes re-targeted with bi-specific monoclonal antibody OC/TR, combined with soluble OC/TR and low-dose recombinant interleukin-2 (IL-2). This treatment had no effect on extraperitoneal disease. Therefore we studied in 13 patients whether this immunotherapeutic protocol resulted only in local or also in systemic immunomodulation. The phenotype of the ex vivo expanded lymphocytes was mainly CD3+, 4-, 8+, 16-, 56-. Their OC/TR-re-targeted cytolytic activity against Igrov-1 ovarian-carcinoma cells was approximately as high in responders as in non-responders. Following most therapeutic cycles, the immunophenotype of lymphocytes recovered from the peritoneal fluid was similar to that of the infused T cells (i.e., mainly CD3+, 4-, 8+) and they were coated with OC/TR. However, cytolytic activity of the recovered lymphocytes against Igrov- 1 cells was low in direct assays, and only slightly increased after additional in vitro re-targeting with OC/TR. Systemically, the i.p. immunotherapy resulted in a transient lymphopenia lasting for about 7 days, low (i.e., 5 to 13 ng/ml) serum concentrations of free, functional OC/TR, and very weak coating of circulating T lymphocytes with OC/TR. These peripheral-blood T lymphocytes did not exert OC/TR-re-targeted cytolytic activity. Thus, locoregional OC/TR-re-targeted cellular immunotherapy resulted in substantial local immunomodulation and anti-tumor effects but virtually no systemic immunomodulation.
AuthorsC H Lamers, R L Bolhuis, S O Warnaar, G Stoter, J W Gratama
JournalInternational journal of cancer (Int J Cancer) Vol. 73 Issue 2 Pg. 211-9 (Oct 09 1997) ISSN: 0020-7136 [Print] United States
PMID9335445 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Bispecific
  • Antibodies, Monoclonal
  • CD3 Complex
Topics
  • Antibodies, Bispecific (therapeutic use)
  • Antibodies, Monoclonal (therapeutic use)
  • Ascitic Fluid (cytology)
  • CD3 Complex (immunology)
  • Cytotoxicity, Immunologic
  • Female
  • Flow Cytometry
  • Humans
  • Immunophenotyping
  • Immunotherapy
  • Infusions, Parenteral
  • Leukapheresis
  • Lymphocyte Activation (immunology)
  • Lymphocyte Count
  • Ovarian Neoplasms (immunology, therapy)
  • T-Lymphocytes (immunology)
  • T-Lymphocytes, Cytotoxic (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: